Pre-made Ligelizumab biosimilar ( Whole mAb, anti-IGHE therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-312
Anti-IGHE therapeutic antibody (Pre-made Ligelizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ligelizumab (INN; development code QGE031) is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. It is an anti-IgE that binds to IGHE an acts as an immunomodulator.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IGHE therapeutic antibody (Pre-made Ligelizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||6uqr:AC|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Urticaria;Allergic asthma;Atopic dermatitis;Bullous pemphigoid|